1289193-46-9Relevant academic research and scientific papers
Imidazopyrazine derivative and synthesis method and application thereof
-
Paragraph 0096; 0111-0115, (2020/12/29)
The invention discloses 6-(6 substituent group-5-sulfonamido-3-pyridine) imidazo [1, 2-a] pyrazine derivatives as shown in a formula (I) or pharmaceutically acceptable salts thereof. The invention also discloses application of the 6-(6-substituent-5-sulfo
Preparation and application of imidazo aromatic ring compounds
-
Paragraph 0125-0126; 0131-0135, (2020/05/02)
The invention provides preparation and application of imidazo aromatic ring compounds, and particularly provides compounds as shown in the following formula I. The definition of each group is as shownin the specification. The compounds have TRK kinase inh
Method for preparing 6-bromine imidazo [1,2-a]pyrazine-3-nonanoic acid-ethyl ester
-
Paragraph 0013; 0014; 0015; 0016; 0017; 0018; 0019; 0020, (2017/08/28)
The invention relates to a method for preparing 6-bromine imidazo [1,2-a]pyrazine-3-nonanoic acid-ethyl ester. 2-amino-5-bromopyrazine, DMF-DMA and ethyl bromoacetate are taken as raw materials, the mass ratio of 2-amino-5-bromopyrazine to DMF-DMA is 1:(0.95-2.2), and the mass ratio of 2-amino-5-bromopyrazine to ethyl bromoacetate is 1:(1.2-3.0). In an appropriate solvent, under the effect of alkali, crude 6-bromine imidazo [1,2-a]pyrazine-3-nonanoic acid-ethyl ester is generated after continuous reaction for 4-13 h at 50-130 DEG C, and pure 6-bromine imidazo [1,2-a]pyrazine-3-nonanoic acid-ethyl ester is obtained after purification. According to the method, the raw materials are easy to obtain, 6-bromine imidazo [1,2-a]pyrazine-3-nonanoic acid-ethyl ester is reasonable in price, heavy metals and corrosive gas are not used in preparation reaction, the reaction is mild, there is no special requirement for a reaction device, and 6-bromine imidazo [1,2-a]pyrazine-3-nonanoic acid-ethyl ester can be produced through an ordinary corrosion-resistant device.
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
-
Page/Page column 346, (2016/04/26)
The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.
COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
Page/Page column 68, (2015/02/19)
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.
COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
Paragraph 00641, (2014/10/04)
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.
